Alcon Showcases Breakthrough Innovations and New Clinical Data at AAO 2025
Alcon will highlight a lineup of new technologies and clinical data at the 2025 American Academy of Ophthalmology (AAO) annual meeting, October 18–20, in Orlando.
At booth #2120, ophthalmologists, surgical staff, and industry leaders will have the opportunity to experience Alcon’s latest advances firsthand—including the Valeda photobiomodulation (PBM) system, the OnAxis Technology software for the LenSx femtosecond laser, and the new prescription treatment for dry eye disease, Tryptyr (acoltremon ophthalmic solution) 0.003%.
“This year marks a defining moment for Alcon,” said Sergio Duplan, Alcon Senior Vice President and President, Americas. “From the launches of Unity VCS | CS, PanOptix Pro, and Ttyptyr to the integration of Valeda PBM, we’ve introduced significant technology across nearly every ophthalmic specialty we support. AAO 2025 is an opportunity to show how these innovations are impacting clinical practice, empowering surgeons, and shaping the future of eye care.”
Alcon’s Unity VCS | CS combined vitreoretinal and cataract system is designed for efficiency and performance. The system features more than a dozen first-to-market technologies and can be experienced in both the combined Unity VCS console and the standalone Unity CS cataract configuration.
Visitors can also explore other 2025 launches, including Clareon PanOptix Pro, Voyager DSLT, wavelight plus, and Adi, each designed to enhance surgical precision and patient outcomes.
Advancing Retina Care with Valeda PBM
Following Alcon’s acquisition of LumiThera, the company has added the Valeda Photobiomodulation System to its retina portfolio. The Valeda PBM is the first and only FDA-approved light therapy proven to improve visual function in patients with dry age-related macular degeneration (AMD) for up to 2 years. Live demonstrations of Valeda PBM will be available at the booth.
Introducing OnAxis Technology for LenSx Laser
For the first time, Alcon’s LenSx femtosecond laser—with more than 4.5 million procedures worldwide—will feature OnAxis Technology for comprehensive astigmatism management. New capabilities include:
Capsular toric markings for precise toric IOL alignment and post-surgical verification
LaserArcs nomogram, which significantly reduces astigmatism in patients undergoing FLACS with arcuate incisions
Advanced fragmentation patterns for customizable lens fragmentation and optimized phaco technique
LenSx with OnAxis Technology is now available to US customers, with demos offered at the Alcon booth.
New Treatment Option for Dry Eye Disease: TRYPTYR
Alcon also introduces Tryptyr (acoltremon ophthalmic solution) 0.003%, a breakthrough neuromodulator eye drop for Dry Eye Disease (DED). Tryptyr is the first prescription eye drop shown to rapidly increase natural tear production as early as day one. Attendees can learn more about this novel therapy and Alcon’s expanding pharmaceutical portfolio at myalcon.com/prescription-drugs.
Scientific and Educational Highlights
Alcon will present several key scientific posters and presentations at AAO 2025, including:
“Results from a Pooled Analysis of Phase 3 Studies of Subjects Treated with Acoltremon 0.003%” – David Wirta, MD (Scientific Poster)
“A Real-World, Prospective, Comparative Study of Post-Operative Chair Time for Advanced Technology Intraocular Lenses” – Satish Modi, MD (Scientific Poster)
“Ray Tracing LASIK (wavelight plus) vs. SMILE for Myopia Correction: A Randomized, Prospective, Contralateral Eye Study” – John Kanellopoulos, MD, Saturday, October 20, 12:30 PM, Room W314
Additional education sessions, product demonstrations, and immersive experiences will be available throughout the meeting.
For detailed information about Alcon’s innovations, research, and product portfolio featured at AAO 2025, visit MyAlconatAAO.com or stop by booth #2120 during the conference.